Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Optibiotix Health Plc | OPTI | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.25 | -1.92% | 12.75 | 10:47:31 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 13.00 | 12.75 | 13.00 | 13.00 |
| Industry Sector |
|---|
| HEALTH CARE EQUIPMENT & SERVICES |
| Top Posts |
|---|
Posted at 06/11/2024 19:55 by putinaire 'Well this is good news. More in hope that expectation I texted him asking when the launch in India of the Dr Morepen jv was due. This is the deal that is planned to deliver GP of £5-6 million a year to Optibiotix (OPTI) within five years'..........ummm kreature6 Nov '24 - 19:37 - 67474 of 67481 0 0 0 Good choice ? ................ New Delhi: Capital markets regulator SEBI on Tuesday barred Morepen Laboratories from the capital markets for one year for making misleading disclosure about the issuance of global depository receipts (GDRs). |
Posted at 30/10/2024 14:17 by putinaire I reckon OPTI spent more on getting advice in the past 8 weeks, than they did on marketing in 10 years. Well, shareholders. Not opti |
Posted at 26/10/2024 18:44 by putinaire OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and skin care, announces the formation of a 100% owned subsidiary, ProBiotix Health Limited ("ProBiotix"), and appointment of Adam Reynolds as Non-Executive Chairman to ProBiotix's Board................. |
Posted at 26/10/2024 18:44 by putinaire 2017OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces it plans to launch products containing its cholesterol reducing strain (LPLDL®) at the Vitafoods Europe Trade Show ("Vitafoods") in Geneva on the 9-11 May 2017. The trade show provides opportunities to connect with 16,500 industry decision makers from the supplements, nutraceutical, functional food and beverage industries. The event is viewed as one of the world's leading trade fairs for the food and drinks industry ............... OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that it has agreed to grant a non-exclusive license agreement to Nutrilinea for the production and commercialisation of products containing OptiBiotix's LPLDL® strain in Europe with a view to maximising the financial return for both parties. .............. OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that HLH BioPharma Vertriebs GmbH ("HLH") have achieved product registration of LPLDL® capsules at IFA GmbH and "Bundesamt für Lebensmittelsicherhe ............... OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that it has entered into a three year supply agreement with Galenicum Special Ingredients, S.L ("Galenicum") to commercialise products containing OptiBiotix's cholesterol and blood pressure reducing strain, LPLDL®. The agreement grants Galenicum a non-exclusive license to commercialise Cardiocare™, a nutritional supplement containing OptiBiotix's LPLDL® in Spain, Chile, Peru and the Middle East with the aim of maximising the financial return for both parties. .............. 2018 OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that it has entered into a production and commercialisation agreement with Fine Foods & Pharmaceuticals N.T.M. S.p.A ("Fine Foods"). The agreement grants Fine Foods an exclusive license for the production and supply of five formulations containing OptiBiotix's LPLDL® strain in Europe in return for royalty payments and a commitment to maximising the financial return for both parties. ............ OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces it has entered into license agreement with ALFASIGMA S.p.A. ("ALFASIGMA") to exclusively commercialise food supplements containing OptiBiotix's cholesterol and blood pressure reducing LPLDL® strain in Italy. ......... |
Posted at 24/10/2024 20:54 by putinaire kreature24 Oct '24 - 21:50 - 67258 of 672600 0 0 I’ll ask the question at the AGM, does Seneca provide stock financing, or supply chain financing to Opti ? Or in anyway assist in revenue recognition ? kreature24 Oct '24 - 21:53 - 67260 of 67260 0 0 0 The other question I want to ask is, can overseas third party manufacturer distribution revenues be recognised at Opti just before the overseas manufacture deducts all cost ? ........ better bring a private security team with you LOL |
Posted at 24/10/2024 19:22 by putinaire They are two wholly independant companies, much like opti and sbtx ....So there is surely an RNS about this deal with opti? Im guessing so. Was it big numbers? |
Posted at 24/10/2024 09:11 by kreature I did say it was prob just a massive oversight. Easy to do with such a round number I guess….Just got to hand the shares back somehow now I suppose ? Or unsell them? DunnoRNS, ……. OptiBiotix Health plc ("OptiBiotix" or the "Company" or "the Group") Total Voting Rights OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare confirms that its issued share capital and total voting rights is 97,943,161. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to issue a notification of their interest in, or of a change in their interest in the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules. The Company is aware that an invalid allotment of 3,125,000 shares ("Invalid Allotment Shares") was entered onto its register in August 2024. This allotment was made as a result of an administrative error by the Company. The Company is in the process of correcting this error. The Invalid Allotment Shares have not been notified to the market nor have they been admitted to trading on AIM. |
Posted at 24/10/2024 08:41 by putinaire OPTI RNS recently, included advice to PBX[... OptiBiotix advised of its recent successful fundraise of £1.35m by the Company and identified lack of market communication by Mr Andersen as the main reason for the failed PBX fundraise. OptiBiotix requested that PBX increase its news flow to potentially support the share price and build positive investor sentiment ...] Did they advise SBTX yesterday too? So more could be sold? |
Posted at 20/8/2024 09:08 by easybrent From lse chat:Looks like poor financial development in H1. In todays RNS they write “Excluding milestone payments received in H2 2023, reported revenues in H1 2024 will be ahead of H2 2023.” Lets go back and see where reported revenue were: H2 2023 £293k H1 2023 £351k H2 2022 £338k The other point to look at is what the milestone payments was in H2, OptiBiotix doesn’t give the precise number but in the 19 Jul 2023 RNS the company wrote “They are paying OptiBiotix a six-figure annual milestone in H2 every year during scale up plus”. If we assume that this milestone payment is £100k which would represent a six-figure milestone payment as per OPTI RNS. Reported revenue for H2 2023 was £293k and excluding the milestone payment it would be £193k. OptiBiotix is writing that revenue in H1 2024 is ahead of this figure, I guess fair estimate is that its in the range of £200-250k. If this is the case H1 2024 revenue is really poor, especially compared to H1 2023 revenue which was £338k. This is supposed to be growth company, but it seems to be shrinking, while the company continues to cherry pick positive development. |
Posted at 15/7/2024 11:11 by institutional investments Institutional Investments - 08 Mar 2024 - 17:16:41 - 65815 of 66446 OptiBiotix - The uncensored thread - OPTIMust be saving that 24.5 dumping beauty as a delayed for Monday. Must be pretty big Vlad The Impaler - 29 Jun 2022 - 10:08:26 - 60128 of 66446 OptiBiotix - The uncensored thread - OPTI The Maker Man has a short order in at 24.5 mid ..... Vlad wtf were we on about back then? |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
